Sirtex shares slammed

Company reports weak first quarter sales growth

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If there's one corporate practice I dislike it is companies that hide bad news inside other announcements.

And it seems the market possibly shares my view with Sirtex Medical (ASX: SRX) shares slammed down more than 5% in lunchtime trading.

In an announcement released after market close yesterday, titled "Sirtex declares a Dividend of 12 cents per share", hidden in the third of four paragraphs, Sirtex stated "In the period preceding the release of the results of our SIRFLOX study Sirtex will continue to grow, although as in the past there will be some fluctuation in the percentage growth rate of dose sales quarter on quarter. This was the case in the first quarter when we experienced subdued dose sales growth."

In other words the company has seen slower growth in dose sales during the three months from July to September. Results of the first quarter sales will be announced in the first week of October, as per usual company practice.

We like management to be up front with shareholders, and while the positive is that the company has noted slowing sales growth before its official report, hiding the bad news in an announcement on its dividend is a black mark against Sirtex. Investors are not that stupid and we don't like being taken for fools (note the lower case 'f').

It also calls into question whether the company is following its corporate disclosure requirements. If the company was aware of slow growth in sales – a potentially material announcement – before yesterday, then the company should have made a separate announcement to the market.

But it seems corporates find it hard to learn from the examples set by their peers, and the mistakes of others. In a separate issue, Newcrest Mining (ASX: NCM) is under investigation by the corporate watchdog, the Australian Securities and Investment Commission (ASIC) for potentially advising some analysts of a fall in production forecasts prior to the news being made public.

Foolish takeaway

The first quarter dose sales numbers are unlikely to have a significant effect on the company's long-term growth prospects. Losing the confidence of investors and the market could have a much more profound effect, so it's in the interests of companies to keep investors properly informed.

Looking to pick up a dividend-paying stock? Discover The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014."

More reading

Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »